George A. Scangos, Ph.D
President and CEO
Exelixis, Inc.

George Scangos received a B.A. in Biology from Cornell University, a Ph.D. from the University of Massachusetts, and was a Jane Coffin Childs Postdoctoral Fellow in the laboratory of Dr. Frank Ruddle at Yale University. While in Dr. Ruddle's laboratory, Dr. Scangos, together with Dr. Jon Gordon, were the first to generate a transgenic mouse. Dr. Scangos then joined the faculty of The Johns Hopkins University, where he currently holds a position as Adjunct Professor. While at Johns Hopkins, Dr. Scangos' laboratory was one of the first to demonstrate that homologous recombination could occur in mammalian cells.

Dr. Scangos left Johns Hopkins in 1986 to work for Bayer Corporation, where he held several positions, including Senior Vice President of Research and Development for Bayer's pharmaceutical division, and then President of Bayer Biotechnology, where he lead an integrated group focused on discovery, development, and manufacture of biological products.

Dr. Scangos has served as President and Chief Executive Officer and Board Member of Exelixis since 1996. He currently serves as Chairman of Anadys Pharmaceuticals, and is on the Board of Entelos, Inc. Dr. Scangos is a member of the Board of Visitors of the University of California, San Francisco School of Pharmacy, the Board of Overseers of the University of California, Davis School of Medicine, and the Advisory Board for the Cornell University Life Sciences Initiative. Dr. Scangos also serves as a member of the Board of the Global Alliance for TB Drug Development.